[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Price Target Trimmed at Morgan Stanley as Policy Risks Ease",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. On December 12, Morgan Stanley cut its price target for Amgen Inc. (NASDAQ:AMGN) from $329 to $304, but kept its Equal Weight rating. The firm’s 2026 biopharma outlook sounds more optimistic, noting that a lot of the policy headaches that dragged […]",
    "url": "https://finnhub.io/api/news?id=80823d8252cd9367c6e638b9f601d8ea8c265564fc202d5df34fb2db98477886",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765912139,
      "headline": "Amgen (AMGN) Price Target Trimmed at Morgan Stanley as Policy Risks Ease",
      "id": 137806344,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. On December 12, Morgan Stanley cut its price target for Amgen Inc. (NASDAQ:AMGN) from $329 to $304, but kept its Equal Weight rating. The firm’s 2026 biopharma outlook sounds more optimistic, noting that a lot of the policy headaches that dragged […]",
      "url": "https://finnhub.io/api/news?id=80823d8252cd9367c6e638b9f601d8ea8c265564fc202d5df34fb2db98477886"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most",
    "summary": "Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.",
    "url": "https://finnhub.io/api/news?id=9cd8737da98198d4adb0874e5e3ba292854fd719e179fe9cc6fa12f9c11a0030",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765894620,
      "headline": "3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most",
      "id": 137816785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.",
      "url": "https://finnhub.io/api/news?id=9cd8737da98198d4adb0874e5e3ba292854fd719e179fe9cc6fa12f9c11a0030"
    }
  },
  {
    "ts": null,
    "headline": "How Amgen’s New CD19-Targeted gMG Approval At Amgen (AMGN) Has Changed Its Investment Story",
    "summary": "Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, making it the first and only CD19-targeted B-cell therapy for this condition with maintenance dosing just twice a year after loading. This latest indication, added to UPLIZNA’s existing approvals in neuromyelitis optica spectrum disorder and IgG4-related disease, further reinforces Amgen’s position in rare, B...",
    "url": "https://finnhub.io/api/news?id=5d4e1a003d5ccf21aeb29e85437e20e85b925881226fa4e94ce2f965b2ba0d3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765865101,
      "headline": "How Amgen’s New CD19-Targeted gMG Approval At Amgen (AMGN) Has Changed Its Investment Story",
      "id": 137800685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Earlier this month, Amgen announced that the FDA approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-AChR and anti-MuSK antibody positive, making it the first and only CD19-targeted B-cell therapy for this condition with maintenance dosing just twice a year after loading. This latest indication, added to UPLIZNA’s existing approvals in neuromyelitis optica spectrum disorder and IgG4-related disease, further reinforces Amgen’s position in rare, B...",
      "url": "https://finnhub.io/api/news?id=5d4e1a003d5ccf21aeb29e85437e20e85b925881226fa4e94ce2f965b2ba0d3f"
    }
  }
]